Výsledky vyhledávání - "Arthur M. Krieg"

Akademický článek

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

Autor: Mark Uhlik, Daniel Pointing, Seema Iyer, Luka Ausec, Miha Štajdohar, Robert Cvitkovič, Matjaž Žganec, Kerry Culm, Valerie Chamberlain Santos, Bronislaw Pytowski, Mokenge Malafa, Hong Liu, Arthur M. Krieg, Jeeyun Lee, Rafael Rosengarten, Laura Benjamin

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

IntroductionMost predictive biomarkers approved for clinical use measure single analytes such as genetic alteration or protein overexpression. We developed and validated a novel biomarker with the aim of achieving broad clinical utility. The Xerna™

Externí odkaz: https://doaj.org/article/3cea1d0d51c242f6bda7d52c9e0ee0df

Zobrazit plný text záznamu

Akademický článek

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC

Autor: Marcelo V. Negrao, MD, Vassiliki A. Papadimitrakopoulou, MD, Andrew C. Price, MD, PhD, Alda L. Tam, MD, MBA, Muhammad Furqan, MD, Sandeep T. Laroia, MD, Erminia Massarelli, MS, MD, PhD, Jose Pacheco, MD, John V. Heymach, MD, PhD, Anne S. Tsao, MD, Gary V. Walker, MD, Lalit Vora, MD, David Mauro, MD, PhD, Heather Kelley, MA, James E. Wooldridge, MD, Arthur M. Krieg, MD, Jiaxin Niu, MD

Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100423- (2023)

Introduction: Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without radiation therapy (RT) in patients with advanced NSCLC. Methods: Pa

Externí odkaz: https://doaj.org/article/375520c714da4dd0a0459208063f6fc7

Zobrazit plný text záznamu

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Autor: Aurélie Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke van Roon, Sabine Sewing, Arthur M. Krieg, Virginia Arechavala-Gomeza, Patrik Andersson

Publikováno v: Nucleic Acid Therapeutics. 33:1-16

The nucleic acid therapeutics field has made tremendous progress in the past decades. Continuous advances in chemistry and design have led to many successful clinical applications, eliciting even more interest from researchers including both academic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d2183c36096e6473337b9648afc92d
https://doi.org/10.1089/nat.2022.0061

Zobrazit plný text záznamu

Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization

Autor: Aaron Morris, Anna E Krug, Sue E. Blackwell, George J. Weiner, Caitlin D Lemke-Miltner, Arthur M. Krieg, Chaobo Yin

Publikováno v: J Immunol

The immunologic and therapeutic effects of intratumoral (IT) delivery of a novel virus-like particle as a lymphoma immunotherapy were evaluated in preclinical studies with human cells and a murine model. CMP-001 is a virus-like particle composed of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20da638b1394695f0a5c2788aa0ea90b
https://doi.org/10.4049/jimmunol.1900742

Zobrazit plný text záznamu

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Autor: Heather Kelley, Rene Gonzalez, Mohammed M. Milhem, Antoni Ribas, David J. Mauro, Jason J. Luke, Aaron Morris, John M. Kirkwood, Theresa Medina, James E. Wooldridge, Bartosz Chmielowski, Arthur M. Krieg, Riyue Bao, George J. Weiner, Diwakar Davar, Katie M. Campbell, Yousef Zakharia

Publikováno v: Cancer discovery, vol 11, iss 12

Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resista

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d408b36e4d84f3a66f114fcfed7fccb
https://pubmed.ncbi.nlm.nih.gov/35363867

Zobrazit plný text záznamu

604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma

Autor: Evan Walters, Michael J McCluskie, Aaron H. Morris, Bassel Akache, Arthur M. Krieg

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Therapeutic options are limited for patients with liver metastases and hepatocellular carcinoma (HCC). Intratumoral and subcutaneous injections of CMP-001, a CpG-A TLR9 agonist packaged within a virus-like particle, have shown evidence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4817483d974cfe5000180688360ec4e
https://doi.org/10.1136/jitc-2020-sitc2020.0604

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání